论文部分内容阅读
目的：研究一种治疗晚期肝癌的新方法。方法：４９ 例无手术指征肝癌患者，行单纯肝动脉栓塞与在肝动脉栓塞的基础上行肝门静脉化疗的对照研究。结果：通过双重化疗后，使无手术指征肝癌的平均生存月数提高到２１．４７ 个月，从而使无手术指征肝癌患者的半年生存率达１００％ ；１ 年生存率达７６．５％ ，２ 年生存率达３５．２９％ ，３ 年生存率达２３．５３％ ，并且使肝癌全身转移的发生率明显下降，而无明显的治疗后副作用。结论：双重化疗是一种能明显提高无手术指征肝癌患者生存期的有效的、安全的治疗方法。
Objective: To study a new method for the treatment of advanced liver cancer. Methods: A total of 49 patients with unresectable hepatocellular carcinoma underwent simple hepatic artery embolization and controlled hepatic portal vein chemotherapy with hepatic artery embolization. Results: After double chemotherapy, the average number of months of survival for no-surgical indication liver cancer was increased to 21.47 months, so that the half-year survival rate of patients with no-surgical indication liver cancer was 100%; the 1-year survival rate was 76.5 %, 2-year survival rate of 35.29%, 3-year survival rate of 23.53%, and the incidence of systemic metastasis of liver cancer decreased significantly, and no obvious side effects after treatment. Conclusions: Dual chemotherapy is an effective and safe treatment that can significantly improve the survival of patients with no-surgical indication liver cancer.